Serum and urine metabolomic biomarkers for predicting prognosis in patients with immunoglobulin A nephropathy
Kidney Research and Clinical Practice
; : 591-605, 2023.
Article
en En
| WPRIM
| ID: wpr-1001999
Biblioteca responsable:
WPRO
ABSTRACT
Immunoglobulin A nephropathy (IgAN) is the most prevalent form of glomerulonephritis worldwide. Prediction of disease progression in IgAN can help to provide individualized treatment based on accurate risk stratification. Methods:
We performed proton nuclear magnetic resonance-based metabolomics analyses of serum and urine samples from healthy controls, non-progressor (NP), and progressor (P) groups to identify metabolic profiles of IgAN disease progression. Metabolites that were significantly different between the NP and P groups were selected for pathway analysis. Subsequently, we analyzed multivariate area under the receiver operating characteristic (ROC) curves to evaluate the predictive power of metabolites associated with IgAN progression.Results:
We observed several distinct metabolic fingerprints of the P group involving the following metabolic pathways glycolipid metabolism; valine, leucine, and isoleucine biosynthesis; aminoacyl-transfer RNA biosynthesis; glycine, serine, and threonine metabolism; and glyoxylate and dicarboxylate metabolism. In multivariate ROC analyses, the combinations of serum glycerol, threonine, and proteinuria (area under the curve [AUC], 0.923; 95% confidence interval [CI], 0.667–1.000) and of urinary leucine, valine, and proteinuria (AUC, 0.912; 95% CI, 0.667–1.000) showed the highest discriminatory ability to predict IgAN disease progression.Conclusion:
This study identified serum and urine metabolites profiles that can aid in the identification of progressive IgAN and proposed perturbed metabolic pathways associated with the identified metabolites.
Texto completo:
1
Índice:
WPRIM
Idioma:
En
Revista:
Kidney Research and Clinical Practice
Año:
2023
Tipo del documento:
Article